Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia

Paul Veys, Robert F. Wynn, Kwang Woo Ahn, Sujith Samarasinghe, Wensheng He, Denise Bonney, John Craddock, Jacqueline Cornish, Stella M. Davies, Christopher C. Dvorak, Reggie E. Duerst, Thomas G. Gross, Neena Kapoor, Carrie Kitko, Robert A. Krance, Wing Leung, Victor A. Lewis, Colin Steward, John E. Wagner, Paul A. CarpenterMary Eapen

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

To determine whether in vivo T-cell depletion, which lowers GVHD, abrogates the antileukemic benefits of myeloablative total body irradiation-based conditioning and unrelated donor transplantation, in the present study, we analyzed 715 children with acute lymphoblastic leukemia. Patients were grouped for analysis according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n = 132) and no in vivo T-cell depletion (n = 392). The median follow-up time was 3.5 years for the ATG group and 5 years for the alemtuzumab and T cell-replete groups. Using Cox regression analysis, we compared transplantation outcomes between groups. Compared with no T-cell depletion, grade 2-4 acute and chronic GVHD rates were significantly lower after in vivo T-cell depletion with ATG (relative risk [RR] = 0.66; P = .005 and RR = 0.55; P < .0001, respectively) or alemtuzumab (RR = 0.09; P < .003 and RR = 0.21; P < .0001, respectively). Despite lower GVHD rates after in vivo T-cell depletion, nonrelapse mortality, relapse, overall survival, and leukemia-free survival (LFS) did not differ significantly among the treatment groups. The 3-year probabilities of LFS after ATG-containing, alemtuzumab-containing, and T cell-replete transplantations were 43%, 49%, and 46%, respectively. These data suggest that in vivo T-cell depletion lowers GVHD without compromising LFS among children with acute lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total body irradiation-based regimens.

Original languageEnglish (US)
Pages (from-to)6155-6161
Number of pages7
JournalBlood
Volume119
Issue number25
DOIs
StatePublished - Jun 21 2012

Fingerprint Dive into the research topics of 'Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this